Fucosyltransferase Engineering Service
Functions of Fucosyltransferase (FucT)
FucT is a class of biosynthetic enzymes involved in the synthesis of fucosylated oligosaccharides. It catalyzes the transfer of L-fucose from the guanosine-diphosphate-L-fucose to a variety of sugar-acceptor substrates, including oligosaccharides, glycoproteins, and glycolipids. Fucosylation of fucose is often the final step in the biosynthesis of oligosaccharides and glycoconjugates. L-fucose-containing glycoconjugates are essential for a wide range of physiological and pathological activities, such as inflammation, bacterial and viral infections, tumor metastasis, genetic disorders, etc. FucTs are highly expressed in liver cancer, lung cancer, epithelial ovarian cancer, colonic carcinoma, etc. They may be involved in metastatic processes, as well as play an important role in the repair of the airway mucosa, and are involved in embryo implantation.
At CD BioGlyco, our FucT engineering service is designed to address this challenge by providing tailored solutions for the rational design and optimization of FUT enzymes. Leveraging our deep expertise in glycoengineering, we enable our clients to precisely control the fucosylation profile of their target molecules, accelerating the development of next-generation biologics with enhanced therapeutic properties.
Key Technologies
Our FucT engineering services rest on a robust framework of advanced genetic engineering technologies, enabling precise control over cellular fucosylation pathways. The core techniques here involve gene knockout, overexpression, silencing, and knockdown. Through these sophisticated genetic tools, we develop stable engineered cell lines that generate glycoproteins with consistent, optimized fucosylation patterns.
Precision FucT Engineering: Empowering Your Biologics
CD BioGlyco optimizes the experimental conditions in the course of long-term cell and mouse research. We provide a variety of cell lines and animal model products for different customers' research needs. Our FUT gene editing service includes the following parts.
- Tumor-associated FUT gene editing service
Abnormalities in tumor cell glycosylation are considered a universal feature of tumor pathogenesis, often manifested as differential expression of abnormal glycoproteins or different carbohydrate epitopes. Fucosylation epitope abnormality is mainly caused by associated FUT expression. We provide FUT2, FUT3, FUT6, FUT7 and FUT8 gene editing services. We will construct corresponding mouse models to detect the effects of related FUT genes on tumor proliferation, metastasis, etc. - Atherosclerosis-related FUT gene editing service
Atherosclerosis is caused by a multifactorial combination of factors. It has become one of the diseases with the highest morbidity and mortality rates. We investigate the biological relationship between FUT genes such as FUT3, FUT4, FUT7, etc., and the development of atherosclerotic disease using mice as a model. FUT-related genes may have synergistic roles in the formation of atherosclerosis. We will also study the relationship between various FUT genes and atherosclerosis according to customers' requirements. - Embryo implantation-related FUT gene editing service
During mammalian reproduction, embryonic cell adhesion and implantation into the endometrium are essential for a successful pregnancy. Embryo implantation occurs during a limited period (implantation window). Many factors (hormones, growth factors, cytokines, etc.) regulate molecular changes in endometrial cells during this critical phase. Glycosylation plays an important role in determining the receptivity of the endometrium to the embryo. FUT is specifically expressed during mammalian reproduction. We have related experiments using rat and mouse models to study the effects of FUT1, FUT4, FUT7, FUT9, etc., on embryo implantation. - Protein O-fucosyltransferase (POFUT) gene editing service
Among the many forms of glycosylation modification, protein O-fucosylation is shown to be closely related to important physiological activities such as animal embryonic development, cell migration, tumor growth, metastasis, etc. POFUT is a key enzyme that catalyzes protein O-fucosylation. It is shown to regulate a series of physiological and pathological processes in animals and humans. We test the function of POFUT in disease development by regulating the expression level of POFUT to provide data support for further treatment and diagnosis of diseases.
In plants, the functions related to O-fucosylation are less studied. Its catalytic key enzyme, namely O-fucosyltransferase (POFUT), lacks systematic research, and O-fucosylation-modifying proteins are not identified. We verify the function of POFUT in plants by overexpression, silencing, Knockdown, and other technologies for gene modification.
Fig.1 One-stop FUT gene editing process. (CD BioGlyco)
Workflow
Published Data
Paper Title: FUT1-mediated terminal fucosylation acts as a new target to attenuate renal fibrosis
Technology: Gene Overexpression
Journal: Molecular Medicine
IF: 5.7
Published: 2023
Results: The results of overexpression of FUT1 in human kidney proximal tubular epithelial cells (HK-2) showed that FUT1 overexpression increased terminal fucoidan glycosylation in HK-2 cells. TGF-β1 stimulation induced HK-2 cells to form a spindle-like shape and detach from neighboring cells. Overexpression of FUT1 is found to further promote TGF-β1-induced aberrant cell morphology. Overexpression of FUT1 combined with TGF-β1 treatment significantly increases the epithelial-mesenchymal transition (EMT) process in HK-2 cells. FUT1-mediated terminal fucosylation could promote renal fibrosis through EMT.
Fig.2 FUT1 promotes renal fibrosis in HK-2 cells. (Luo, et al., 2023)
Applications
- Technologies for FUT gene editing are used to study the role of FUT in disease development and thus to develop potent and selective inhibitors against specific FucT.
- Systematic studies of FUcT in plants are lacking. O-fucosylation-modified proteins are not identified. Technologies for FUT gene editing are used to study its function in plants.
- FUT is associated with physiological activities such as embryo implantation in organisms. Technologies for FUT gene editing have a role in regulating physiological activities.
Highlights
- We have a diverse range of animal models. Multiple requirements of clients are fulfilled.
- We have an experienced team. The efficiency of editing is improved by optimizing the experimental process.
- Technologies for FUT gene editing help deepen the understanding of the biology of different diseases and provide the basis for the development of new therapeutic strategies.
Frequently Asked Questions
CD BioGlyco has rich experience in cell biology, molecular biology, in vitro biology, and other fields. We provide a complete set of gene editing services. In addition to FucT, we also provide Sialyltransferase Engineering Service and Glucuronyltransferase Engineering Service. If you want to know more about them, please feel free to contact us.
Associated Services
Our team synthesizes complex fucosylated glycans for use as substrates or standards.
Our antibody glycoengineering service address a wide range of modifications beyond fucosylation.
Reference
- Luo, J.; et al. FUT1-mediated terminal fucosylation acts as a new target to attenuate renal fibrosis. Molecular Medicine. 2023, 29(1): 55. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




